GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Memphasys Ltd (FRA:IG7) » Definitions » General and Admin. Expense

Memphasys (FRA:IG7) General and Admin. Expense : €0.75 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Memphasys General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Memphasys's General and Admin. Expense for the six months ended in Dec. 2023 was €0.50 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023 was €0.75 Mil.

Memphasys General and Admin. Expense Historical Data

The historical data trend for Memphasys's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Memphasys General and Admin. Expense Chart

Memphasys Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.70 0.78 0.73 0.36

Memphasys Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.46 0.11 0.25 0.50

Memphasys General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Memphasys General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of Memphasys's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Memphasys (FRA:IG7) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Memphasys Ltd (FRA:IG7) » Definitions » General and Admin. Expense
Comparable Companies
ASX:AVE ASX:ATX ASX:ANR ASX:ZLD ASX:TRP ASX:BTC ASX:VBS ASX:NSB ASX:BGT ASX:ILA OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
MEM:Australia
Address
30 Richmond Road, Homebush, Sydney, NSW, AUS, 2140
Website
https://www.memphasys.com
Memphasys Ltd is an Australian-based emerging small-cap reproductive biotechnology company. It develops and commercializes novel reproduction and fertility solutions for humans and animals. Its technology includes Hydrogel and other polymer membrane technology development. The company is developing novel medical devices, diagnostics, and media with applications to assisted reproduction technologies, including IVF in humans and artificial insemination in animals.

Memphasys (FRA:IG7) Headlines

No Headlines